🇺🇸 FDA
Pipeline program

Gamma hydroxybutyric

NIDA-00191-2

Phase 2 small_molecule terminated

Quick answer

Gamma hydroxybutyric for Opioid-Related Disorders is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Opioid-Related Disorders
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials